Clinical TrialApr 21, 2026, 10:01 AM
Cardiff Oncology to Present Phase 2 mCRC Data at ASCO 2026
AI Summary
Cardiff Oncology announced it will present updated data from its CRDF-004 Phase 2 clinical trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluates onvansertib in combination with standard of care regimens for patients with first-line RAS-mutated metastatic colorectal cancer. This presentation provides an important update on the company's clinical development progress and offers an opportunity to share findings with the oncology community.
Key Highlights
- Cardiff Oncology to present updated data from CRDF-004 Phase 2 trial.
- Presentation scheduled for June 2, 2026, at ASCO Annual Meeting.
- Trial evaluates onvansertib for first-line RAS-mutated mCRC.
- Abstract number 3510 will be publicly available May 21, 2026.
Price Impact
More from CRDF